샘플 요청 목록

 카트 문의
시장보고서
상품코드
1760783

세계의 멀티플렉스 어세이 시장

Multiplex Assays
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 158 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

멀티플렉스 어세이 세계 시장은 2030년까지 60억 달러에 이를 전망

2024년에 41억 달러로 추정되는 멀티플렉스 어세이 세계 시장은 2024-2030년간 CAGR 6.4%로 성장하여 2030년에는 60억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 소모품은 CAGR 6.9%를 나타내고, 분석 기간 종료시에는 37억 달러에 이를 것으로 예측됩니다. 기기 부문의 성장률은 분석 기간중 CAGR 5.4%로 추정됩니다.

미국 시장은 11억 달러로 추정, 중국은 CAGR 9.6%로 성장 예측

미국의 멀티플렉스 어세이 시장은 2024년에 11억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 14억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 9.6%로 예상됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 3.5%와 6.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.8%를 보일 전망입니다.

세계 멀티플렉스 어세이 시장 - 주요 동향 및 촉진요인 정리

멀티플렉스 어세이이란 무엇이며, 조사 및 진단에 어떻게 사용됩니까?

멀티플렉스 어세이은 하나의 시료에서 여러 생물학적 마커(단백질, 유전자, 기타 분자 등)를 동시에 검출하고 분석할 수 있는 첨단 진단 도구입니다. 이러한 분석은 복잡한 생물학적 과정을 분석하거나 보다 높은 정확도와 효율로 질병을 검출하기 위해 연구, 임상 진단, 의약품 개발에 널리 사용되고 있습니다. 한 번에 하나의 분석물을 측정하는 기존 분석법과는 달리, 멀티플렉스 어세이법은 여러 타겟을 동시에 평가하여 종합적인 개요를 제공함으로써 시간을 절약하고 비용을 절감하며 데이터 처리량을 향상시킵니다. 이러한 분석은 종양학, 면역학, 감염학 등의 분야에서 여러 바이오마커를 이해함으로써 보다 정확한 진단과 맞춤 치료 전략으로 이어질 수 있는 필수적인 요소입니다.

멀티플렉스 어세이의 미래를 좌우할 기술 발전은 무엇인가?

생명공학 및 분자진단학의 발전은 멀티플렉스 어세이법을 더욱 민감하고, 정확하고, 확장 가능한 것으로 변화시키고 있습니다. 차세대 시퀀싱(NGS) 기술과 마이크로어레이 플랫폼의 개발로 대량의 유전자 및 단백질 데이터를 동시에 분석할 수 있는 능력이 크게 향상되었습니다. 또한, 형광 및 화학발광 검출법의 발전으로 멀티플렉스 어세이의 민감도와 정확도가 향상되어 저농도의 바이오마커를 검출할 수 있게 되었습니다. 인공지능(AI) 및 머신러닝과의 통합을 통해 보다 정교한 데이터 분석이 가능해져 연구자와 임상의가 복잡한 분석 결과를 보다 효과적으로 해석할 수 있게 되었습니다. 이러한 혁신으로 인해 동반진단, 바이오마커 탐색, 맞춤의료 등의 분야에서 멀티플렉스 어세이의 활용이 확대되고 있습니다.

개인 맞춤형 의료로의 전환이 멀티플렉스 어세이에 대한 수요를 어떻게 촉진하고 있는가?

환자별 유전자, 분자, 환경적 프로파일을 기반으로 환자 개개인에 맞는 치료를 제공하는 맞춤의료 증가로 인해 멀티플렉스 어세이에 대한 수요가 크게 증가하고 있습니다. 이러한 분석을 통해 의료 서비스 제공업체는 한 번에 여러 바이오마커를 분석하여 환자의 건강 상태와 질병 상태를 보다 종합적으로 이해할 수 있습니다. 예를 들어, 종양학에서 멀티플렉스 어세이은 표적 치료를 안내하는 특정 돌연변이 및 유전자 발현을 식별하는 데 사용됩니다. 하나의 검사로 여러 질병 관련 마커를 검출하고 모니터링할 수 있게 됨에 따라 여러 결과를 동시에 평가할 수 있게 되어 의약품 개발 및 임상시험의 효율성이 향상되고 있습니다. 이러한 개인 맞춤형 정밀의료에 대한 노력은 멀티플렉스 어세이 시장의 큰 성장 동력으로 작용하고 있습니다.

멀티플렉스 어세이 시장의 주요 성장 촉진요인은 무엇인가?

멀티플렉스 어세이 시장의 성장은 분자진단의 발전, 만성 질환의 유병률 증가, 개인 맞춤형 의료에 대한 수요 증가 등 여러 가지 요인에 기인합니다. 하이스루풋 플랫폼 및 향상된 검출 방법의 개발과 같은 기술 혁신은 멀티플렉스 어세이의 정확도를 향상시키고 더 넓은 범위의 응용 분야에 적용될 수 있도록 하고 있습니다. 암 및 기타 복잡한 질환의 발생률이 증가함에 따라 여러 바이오마커를 이해하는 것이 진단과 치료에 필수적인 연구 및 임상 현장에서 이러한 분석법의 채택이 증가하고 있습니다. 또한, 환자를 특정 치료법에 맞게 조정하기 위해 멀티플렉스 어세이이 사용되는 동반 진단의 확대로 인해 수요가 더욱 증가하고 있습니다. 제약 개발, 특히 바이오마커 중심의 신약 임상시험에서 멀티플렉스 어세이의 사용이 증가하고 있는 것도 시장 성장의 주요 요인으로 작용하고 있습니다.

부문

제공(소모품, 기기, 소프트웨어＆서비스);유형(단백질 어세이, 핵산 어세이, 세포 기반 어세이);최종사용자(제약＆바이오테크놀러지 기업, 병원＆연구기관, 참조 실험실, 기타 최종사용자)

조사 대상 기업 예(총 11개사)

  • Abcam PLC
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Illumina, Inc.
  • Luminex Corporation
  • Merck KgaA
  • Meso Scale Diagnostics, LLC.
  • Olink
  • Qiagen NV
  • Quanterix Corporation
  • Randox Laboratories Ltd.
  • Seegene, Inc.
  • Thermo Fisher Scientific, Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.07

Global Multiplex Assays Market to Reach US$6.0 Billion by 2030

The global market for Multiplex Assays estimated at US$4.1 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.6% CAGR

The Multiplex Assays market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Multiplex Assays Market - Key Trends & Drivers Summarized

What Are Multiplex Assays and How Are They Used in Research and Diagnostics?

Multiplex assays are advanced diagnostic tools that allow the simultaneous detection and analysis of multiple biological markers (such as proteins, genes, or other molecules) in a single sample. These assays are widely used in research, clinical diagnostics, and drug development to analyze complex biological processes or detect diseases with higher accuracy and efficiency. Unlike traditional assays that measure one analyte at a time, multiplex assays provide a comprehensive overview by assessing multiple targets simultaneously, thus saving time, reducing costs, and increasing data throughput. These assays are essential in fields like oncology, immunology, and infectious diseases, where understanding multiple biomarkers can lead to more accurate diagnoses and personalized treatment strategies.

What Technological Advances Are Shaping the Future of Multiplex Assays?

Advancements in biotechnology and molecular diagnostics are transforming multiplex assays, making them more sensitive, accurate, and scalable. The development of next-generation sequencing (NGS) technologies and microarray platforms has significantly enhanced the ability to analyze large volumes of genetic and protein data simultaneously. Furthermore, advances in fluorescent and chemiluminescent detection methods have improved the sensitivity and precision of multiplex assays, allowing for the detection of lower concentrations of biomarkers. Integration with artificial intelligence (AI) and machine learning is enabling more sophisticated data analysis, helping researchers and clinicians interpret complex assay results more effectively. These technological innovations are expanding the use of multiplex assays in areas such as companion diagnostics, biomarker discovery, and personalized medicine.

How Is the Shift Toward Personalized Medicine Driving the Demand for Multiplex Assays?

The growing trend toward personalized medicine, which tailors treatments to individual patients based on their unique genetic, molecular, and environmental profiles, is significantly boosting the demand for multiplex assays. These assays enable healthcare providers to analyze multiple biomarkers at once, offering a more comprehensive understanding of a patient’s health and disease status. In oncology, for example, multiplex assays are being used to identify specific mutations or gene expressions that can guide targeted therapies. The ability to detect and monitor several disease-related markers in a single test is also enhancing the efficiency of drug development and clinical trials, where multiple outcomes can be evaluated simultaneously. This push toward more personalized and precise healthcare is a major growth driver for the multiplex assays market.

What Are the Key Growth Drivers in the Multiplex Assays Market?

The growth in the multiplex assays market is driven by several factors, including advancements in molecular diagnostics, the rising prevalence of chronic diseases, and the increasing demand for personalized medicine. Technological innovations, such as the development of high-throughput platforms and enhanced detection methods, are making multiplex assays more accurate and accessible for a wider range of applications. The growing incidence of cancer and other complex diseases is also pushing the adoption of these assays in research and clinical settings, where understanding multiple biomarkers is critical for diagnosis and treatment. Additionally, the expansion of companion diagnostics, where multiplex assays are used to match patients with specific therapies, is further driving demand. The increasing use of multiplex assays in pharmaceutical development, especially in the context of biomarker-driven drug trials, is another significant factor contributing to market growth.

SCOPE OF STUDY:

The report analyzes the Multiplex Assays market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Consumables, Instruments, Software & Services); Type (Protein Assays, Nucleic Acid Assays, Cell-Based Assays); End-Use (Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 11 Featured) -

  • Abcam PLC
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Illumina, Inc.
  • Luminex Corporation
  • Merck KgaA
  • Meso Scale Diagnostics, LLC.
  • Olink
  • Qiagen NV
  • Quanterix Corporation
  • Randox Laboratories Ltd.
  • Seegene, Inc.
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Multiplex Assays - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for High-Throughput Diagnostic Testing Drives Adoption of Multiplex Assays
    • Rising Prevalence of Chronic and Infectious Diseases Expands Addressable Market for Multiplex Assays in Diagnostics
    • Increasing Focus on Personalized Medicine and Biomarker Discovery Strengthens Business Case for Multiplex Assays
    • Growth in Pharmaceutical R&D and Drug Development Fuels Demand for Multiplex Assays in Drug Screening
    • Technological Advancements in Multiplex Assay Platforms Propel Innovation in Precision Diagnostics
    • Rising Use of Multiplex Assays in Oncology Expands Opportunities for Cancer Diagnosis and Treatment
    • Increasing Adoption of Multiplex Assays in Immunology Research Strengthens Market for Comprehensive Immune Profiling
    • Growth in Point-of-Care Testing Drives Demand for Rapid Multiplex Diagnostic Assays
    • Increasing Focus on Reducing Healthcare Costs and Improving Diagnostic Efficiency Expands Market for Multiplex Assays
    • Technological Advancements in Microfluidics and Lab-on-a-Chip Platforms Propel Growth in Multiplex Assay Development
    • Rising Adoption of Multiplex Assays in Vaccine Development Strengthens Business Case for High-Throughput Screening
    • Growth in Demand for Multiplex Assays in Infectious Disease Testing Expands Market for Pandemic Preparedness
    • Increasing Use of Multiplex Assays in Clinical Trials Drives Growth in Pharmaceutical and Biotechnology Applications
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Protein Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Protein Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Protein Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Nucleic Acid Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Nucleic Acid Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Nucleic Acid Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Cell-based Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Cell-based Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Cell-based Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Hospitals & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Hospitals & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Multiplex Assays Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Multiplex Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Multiplex Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Multiplex Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Multiplex Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Multiplex Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제